These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25411114)

  • 1. Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics.
    Fathallah AM; Balu-Iyer SV
    J Pharm Sci; 2015 Feb; 104(2):301-6. PubMed ID: 25411114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous administration of biotherapeutics: current experience in animal models.
    McDonald TA; Zepeda ML; Tomlinson MJ; Bee WH; Ivens IA
    Curr Opin Mol Ther; 2010 Aug; 12(4):461-70. PubMed ID: 20677097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge.
    Sánchez-Félix M; Burke M; Chen HH; Patterson C; Mittal S
    Adv Drug Deliv Rev; 2020 Dec; 167():66-77. PubMed ID: 32473188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.
    Bittner B; Richter W; Schmidt J
    BioDrugs; 2018 Oct; 32(5):425-440. PubMed ID: 30043229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous delivery of biotherapeutics: challenges at the injection site.
    Sequeira JAD; Santos AC; Serra J; Estevens C; Seiça R; Veiga F; Ribeiro AJ
    Expert Opin Drug Deliv; 2019 Feb; 16(2):143-151. PubMed ID: 30632401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic determinants of biotherapeutics absorption following SC administration.
    Richter WF; Bhansali SG; Morris ME
    AAPS J; 2012 Sep; 14(3):559-70. PubMed ID: 22619041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous absorption of biotherapeutics: knowns and unknowns.
    Richter WF; Jacobsen B
    Drug Metab Dispos; 2014 Nov; 42(11):1881-9. PubMed ID: 25100673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components.
    Kinnunen HM; Sharma V; Contreras-Rojas LR; Yu Y; Alleman C; Sreedhara A; Fischer S; Khawli L; Yohe ST; Bumbaca D; Patapoff TW; Daugherty AL; Mrsny RJ
    J Control Release; 2015 Sep; 214():94-102. PubMed ID: 26210441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
    Brennan BJ; Xu ZX; Grippo JF
    Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.
    Anderson KC; Landgren O; Arend RC; Chou J; Jacobs IA
    Future Oncol; 2019 Oct; 15(28):3267-3281. PubMed ID: 31394933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins.
    Zou P; Wang F; Wang J; Lu Y; Tran D; Seo SK
    J Control Release; 2021 Aug; 336():310-321. PubMed ID: 34186147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics.
    Curreri AM; Kim J; Dunne M; Angsantikul P; Goetz M; Gao Y; Mitragotri S
    Adv Sci (Weinh); 2023 Mar; 10(7):e2205389. PubMed ID: 36642846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements.
    Badkar AV; Gandhi RB; Davis SP; LaBarre MJ
    Drug Des Devel Ther; 2021; 15():159-170. PubMed ID: 33469268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous delivery of monoclonal antibodies: How do we get there?
    Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ
    J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.
    Turner MR; Balu-Iyer SV
    J Pharm Sci; 2018 May; 107(5):1247-1260. PubMed ID: 29336981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of gonadotropin-releasing hormone: comparison of subcutaneous and intravenous routes.
    Handelsman DJ; Jansen RP; Boylan LM; Spaliviero JA; Turtle JR
    J Clin Endocrinol Metab; 1984 Oct; 59(4):739-46. PubMed ID: 6384253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness.
    Thomas JR; Wallace MS; Yocum RC; Vaughn DE; Haller MF; Flament J
    J Pain Symptom Manage; 2009 Nov; 38(5):663-72. PubMed ID: 19819665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes.
    Marcucci G; Silverman L; Eller M; Lintz L; Beach CL
    J Clin Pharmacol; 2005 May; 45(5):597-602. PubMed ID: 15831784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of sulfamethoxypyridazine following intramuscular or subcutaneous administration in goats.
    Garg SK; Uppal RP
    Vet Res; 1997; 28(1):101-4. PubMed ID: 9172837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Human Bioavailability of Subcutaneously Administered Fusion Proteins and Monoclonal Antibodies Using Human Intravenous Clearance or Antibody Isoelectric Point.
    Zou P
    AAPS J; 2023 Mar; 25(3):31. PubMed ID: 36959523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.